Clinical significance of slightly reduced von Willebrand factor activity
- PMID: 31990275
- DOI: 10.20452/pamw.15162
Clinical significance of slightly reduced von Willebrand factor activity
Abstract
Von Willebrand disease (VWD) is the most common congenital bleeding disorder, with a clinical presentation of mucocutaneous and surgical bleeding varying from mild to severe. It is inherited in an autosomal dominant or autosomal recessive manner. The disease is caused by quantitative or qualitative deficiency of the von Willebrand factor (VWF) and is classified as type 1, 2 (2A, 2B, 2M, 2N), and 3. Although type 1 VWD is the most common form of VWD, the f ormal cutoff for diagnosis remains a subject of debate. In our paper, we present results of studies regarding the clinical and laboratory importance of a new type of bleeding disorder called low VWF. The new guidelines for VWD diagnosis and management suggested that patients with historically type 1 VWD should be divided into 2 subsets: type 1 VWD with a VWF antigen level (VWF:Ag) of less than 30 IU/dl or less than 40 IU/dl, in which about 80% of patients exhibited VWF gene mutations, and low VWF with a VWF:Ag level of 30 to 50 IU/dl or 40 to 50 IU/dl, in which the causative mutation is detected in merely 40% of patients and in most families, inheritance is not dependent on the locus of VWF on chromosome 12. Previously, moderately reduced VWF levels (30-50 IU/dl) were considered a risk factor for bleeding, but not a true bleeding disorder, and this condition was named low VWF. Recently, it was documented in a large group of patients with type 1 VWD and low VWF that bleeding score does not correlate with VWF:Ag and bleeding symptoms in type 1 VWD (<30 IU/dl) and low VWF can change from infrequent and moderate to severe bleeds. Because the plasma concentration of VWF depends on many physiological and pathological factors that may mask the diagnosis of VWD, separation of the group of patients with low VWF (30-50 IU/dl) from those with type 1 VWD may delay or prevent them from receiving appropriate treatment. Diagnosis of VWD in each case, particularly those with a slight decrease in VWF (30-50 IU/dl), should be based primarily on the clinical manifestations and family history of hemorrhagic diathesis.
Similar articles
-
Unravelling the spectrum of von Willebrand factor variants in quantitative von Willebrand disease: results from a German cohort study.J Thromb Haemost. 2024 Nov;22(11):3010-3034. doi: 10.1016/j.jtha.2024.06.026. Epub 2024 Jul 11. J Thromb Haemost. 2024. PMID: 39002731
-
Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.Acta Haematol. 2009;121(2-3):128-38. doi: 10.1159/000214853. Epub 2009 Jun 8. Acta Haematol. 2009. PMID: 19506359 Review.
-
Laboratory diagnosis and molecular classification of von Willebrand disease.Acta Haematol. 2009;121(2-3):71-84. doi: 10.1159/000214846. Epub 2009 Jun 8. Acta Haematol. 2009. PMID: 19506352 Review.
-
Diagnosis of inherited von Willebrand disease: a clinical perspective.Semin Thromb Hemost. 2006 Sep;32(6):555-65. doi: 10.1055/s-2006-949661. Semin Thromb Hemost. 2006. PMID: 16977566 Review.
-
Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.Semin Thromb Hemost. 2005 Nov;31(5):577-601. doi: 10.1055/s-2005-922230. Semin Thromb Hemost. 2005. PMID: 16276467 Review.
Cited by
-
Nanotopography of Polystyrene/Poly(methyl methacrylate) for the Promotion of Patient Specific Von Willebrand Factor Entrapment and Platelet Adhesion in a Whole Blood Microfluidic Assay.Polymers (Basel). 2023 Mar 22;15(6):1580. doi: 10.3390/polym15061580. Polymers (Basel). 2023. PMID: 36987359 Free PMC article.
-
Reevaluation of von Willebrand disease diagnosis in a Croatian paediatric cohort combining bleeding scores, phenotypic laboratory assays and next generation sequencing: a pilot study.Biochem Med (Zagreb). 2022 Feb 15;32(1):010707. doi: 10.11613/BM.2022.010707. Biochem Med (Zagreb). 2022. PMID: 35210927 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous